AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.120

+0.02020.00%

Volume:213.79K

Turnover:24.37K

Market Cap:59.08M

PE:-3.61

High:0.120

Open:0.105

Low:0.105

Close:0.100

Loading ...

Overview Company News Filings

Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%

MT Newswires Live

Neurizon Therapeutics announces strong safety results in latest study

The Market Herald

Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line

MT Newswires Live

Neurizon finds positive results for lead drug in 3D brain model study

The Market Herald

ASX Biggest Gainers

MT Newswires Live

‘Maximising the potential’: Neurizon prepares for HEALEY study of ALS

The Market Herald

Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%

MT Newswires Live

Here's Why We're Watching Neurizon Therapeutics' (ASX:NUZ) Cash Burn Situation

Simply Wall St.

Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain

Simply Wall St.

BRIEF-Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln

Neurizon Therapeutics Ltd - Hy Loss Attributable a$7.3 Mln

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold

Neurizon Therapeutics - Got Guidance From US FDA Placing Co's Ind Application for Nuz-001 Under Clinical Hold

THOMSON REUTERS

Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%

MT Newswires Live

BRIEF-Neurizon Therapeutics Says US Patent Granted For NUZ-001

BUZZ-Australia's Neurizon Therapeutics rise on US patent approval

Neurizon snags US patent for NUZ-001 after winning FDA orphan status in 2024

The Market Herald

Neurizon Therapeutics Ltd - US Patent Granted for Nuz-001 for Treatment of Neurodegenerative Diseases

THOMSON REUTERS

ASX Market Update: Rio Tinto & Glencore in merger talks | January 17, 2025

The Market Herald

BUZZ-Australia's Neurizon Therapeutics slides after FDA puts drug application on hold

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NUZ.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.12,"timestamp":1744870320000,"preClose":0.1,"halted":0,"volume":213792,"delay":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":492305766,"eps":-0.033278,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"04-17 16:12:00 AEST","open":0.105,"high":0.12,"low":0.105,"amount":24366,"amplitude":0.15,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.033278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.1,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":1.458994444797578,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.46%","roe":"-150.50%","lyrEps":-0.020692,"volumeRatio":1.458994444797578,"shares":492305766,"dividePrice":0,"high":0.12,"amplitude":0.15,"preClose":0.1,"low":0.105,"week52Low":0.096,"pbRate":"4.96","psRate":"38.97","week52High":0.31,"institutionHeld":0,"latestPrice":0.12,"eps":-0.033278,"divideRate":0,"volume":213792,"delay":0,"ttmEps":-0.033278,"open":0.105,"prevYearClose":0.17,"prevWeekClose":0.12,"prevMonthClose":0.13,"prevQuarterClose":0.13,"fiveDayClose":0.099,"twentyDayClose":0.1,"sixtyDayClose":0.115},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528758703","title":"Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528758703","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528758703?lang=en_us&edition=fundamental","pubTime":"2025-04-17 13:25","pubTimestamp":1744867541,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  appointed Kathryn Williams as chief regulatory officer, Jeffrey Brown as chief scientific adviser, and Chris Freitag as chief medical adviser, according to a Thursday Australian bourse filing.Williams has 20 years of experience in regulatory affairs, securing fast track and orphan designations with regulatory bodies, the filing said.Brown also has over 20 years of experience in drug development experience in neurology programs.Freitag is a medical doctor with nearly 30 years of medical and pharmaceutical experience focusing on oncology and rare diseases.The company's shares rose 15% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK7096","NUZ.AU","LENZ","BK4139"],"gpt_icon":0},{"id":"2527922973","title":"Neurizon Therapeutics announces strong safety results in latest study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527922973","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527922973?lang=en_us&edition=fundamental","pubTime":"2025-04-14 12:30","pubTimestamp":1744605000,"startTime":"0","endTime":"0","summary":"Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics  has confirmed this week.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.“This is a very positive result,” Dr Michael Thurn told HotCopper, declaring on the company’s news: “We have been able to show NUZ-001 may have the potential to be a treatment for Alzheimer’s disease and Parkinson’s disease.”“As you know, they are diseases that are becoming more and more important in aging populations so these results really set us up to look at these two indications going forward.”NUZ has been trading 4.7% lower on Monday and is now selling at 10cps.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizon-therapeutics-announces-strong-safety-results-in-latest-study-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LENZ","NUZ.AU","BK4007","BK4139","BK7096"],"gpt_icon":0},{"id":"2524337278","title":"Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2524337278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524337278?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:39","pubTimestamp":1743748793,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said it completed an additional independent study in partnership with a research group at the University of Queensland, to investigate the acute effects of its NUZ-001 drug candidate on the survival of mouse NSC-34 motor neurons following exposure to TDP-43 aggregates and link any changes in viability to enhanced autophagy, according to a Friday Australian bourse filing.Preliminary data suggests that NUZ-001 had a small but significant effect on TDP-43-mediated cell death in the motor neuron cell line. However, despite enhancing survival, acute treatment with NUZ-001 showed no effect on autophagy markers.Autophagy is a critical process for maintaining neural homeostasis, which is recognized as a key therapeutic target in neurodegenerative diseases, the filing said.Researchers treated NSC-34 cells with various concentrations of the drug candidate and compared it to Rapamycin, an autophagy activator over four hours.They analyzed key markers of autophagy activation ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","LENZ","BK4139","BK7096"],"gpt_icon":0},{"id":"2524184320","title":"Neurizon finds positive results for lead drug in 3D brain model study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524184320","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524184320?lang=en_us&edition=fundamental","pubTime":"2025-04-01 08:53","pubTimestamp":1743468780,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd  has yielded positive results from an independent study – conducted in collaboration with Tessara Therapeutics – which showed its lead drug NUZ-001 produced several positive effects on the brain.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The study analysed the effects of the drug candidate on Tessara’s RealBrain 3D human tissues model – a 3D model of the brain – and found both NUZ-001 and NUZ-001 Sulfone  were safe when applied to a healthy human brain.The two tested drugs also reportedly provided neuroprotective properties against neurotoxic insult  and encouraged the health of brain tissues.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full discl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizon-finds-positive-results-for-lead-drug-in-3d-brain-model-study-2025-04-01/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2522156569","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2522156569","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522156569?lang=en_us&edition=fundamental","pubTime":"2025-03-28 10:01","pubTimestamp":1743127305,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday:Renerve : +40.9%, AU$0.155Elementos : +19.1%, AU$0.081ADX Energy : +16.7%, AU$0.028Recharge Metals : +16.7%, AU$0.014RAREX : +15%, AU$0.023Neurizon Therapeutics : +14.3%, AU$0.12Black Cat Syndicate : +14%, AU$0.895Adneo : +14%, AU$0.049Caprice Resources : +13.7%, AU$0.083New Murchison Gold : +13.3%, AU$0.017","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","BK7002","NUZ.AU","CRS.AU","ADX.AU","ELT.AU","REE.AU","BK7503","BC8.AU","BK7126","BK7142","NMG.AU","AD1.AU","BK7096","RNV.AU","REC.AU","BK7095"],"gpt_icon":0},{"id":"2521731506","title":"‘Maximising the potential’: Neurizon prepares for HEALEY study of ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2521731506","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521731506?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:05","pubTimestamp":1742778300,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, double-blind, adaptive study that will assess the safety and efficacy of various investigational products for treatment of amyotrophic lateral sclerosis .Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The headlining news is the HEALEY treatment period for the trial is being extended from 24 to 36 weeks to enable a longer evaluation of treatment effects.The study will also be enriched for fast progressors, the company said, through a shift in the “show time for symptom onset,” from 36 to 24 months. On top of that, peripheral blood mononuclear cell collection has been added to aid future research and therapy development.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/maximising-the-potential-neurizon-prepares-for-healey-study-of-als-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2520755140","title":"Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520755140","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520755140?lang=en_us&edition=fundamental","pubTime":"2025-03-17 11:30","pubTimestamp":1742182210,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  will begin \"in the coming weeks\" the two pharmacokinetic studies that are necessary to lift the clinical suspension on its investigational new drug application for NUZ-001, according to a Monday filing with the Australian bourse.The US Food and Drug Administration placed the application for NUZ-001 under clinical hold last January amid concerns about the adequacy of relevant information, raising potential risks to human subjects.Neurizon said the two upcoming pharmacokinetic studies will provide additional animal exposure data specifically requested by the US FDA to assess the adequacy of systemic exposure to NUZ-001. A formal response from the regulator is expected within the next 60 days, the filing stated.Neurizon expects the studies to cost between AU$400,000 and AU$600,000, which is eligible for a government R&D rebate, per the filing.The biotechnology company is developing NUZ-001 for the treatment of amyotrophic lateral sclerosis or ALS, which is the most ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK4139","BK7096","LENZ"],"gpt_icon":0},{"id":"2513554592","title":"Here's Why We're Watching Neurizon Therapeutics' (ASX:NUZ) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2513554592","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513554592?lang=en_us&edition=fundamental","pubTime":"2025-02-21 08:31","pubTimestamp":1740097904,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/heres-why-were-watching-neurizon-therapeutics-asxnuz-cash-bu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NUZ.AU","LENZ","BK7096"],"gpt_icon":0},{"id":"2512074191","title":"Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2512074191","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512074191?lang=en_us&edition=fundamental","pubTime":"2025-02-19 04:19","pubTimestamp":1739909975,"startTime":"0","endTime":"0","summary":"While Neurizon Therapeutics Limited  shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 24% in the last quarter. On the other hand the returns over the last half decade have not been bad. After all, the stock has performed better than the market (51%) in that time, and is up 54%. While the long term returns are impressive, we do have some sympathy for those who bought more recently, given the 41% drop, in the last year.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.Over the last half decade Neurizon Therapeutics' revenue has actually been trending down at about 18% per year. Despite the lack of revenue growth, the stock has returned a respectable 9%, compound, over that time. It's probably worth checking other factors such as the profitability, to try to understand the share price action. It may not be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investing-neurizon-therapeutics-asx-nuz-201935674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NUZ.AU","LENZ","BK4139","BK7096"],"gpt_icon":0},{"id":"2512235992","title":"BRIEF-Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2512235992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512235992?lang=en_us&edition=fundamental","pubTime":"2025-02-17 14:05","pubTimestamp":1739772318,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Logs HY Loss Attributable A$7.3 MlnFeb 17 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:HY LOSS ATTRIBUTABLE A$7.3 MILLIONHY OTHER INCOME A$1.8 MILLIONFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nFWN3OR2D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2512993743","title":"Neurizon Therapeutics Ltd - Hy Loss Attributable a$7.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2512993743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512993743?lang=en_us&edition=fundamental","pubTime":"2025-02-17 11:28","pubTimestamp":1739762935,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nFWN3OR2D8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2512964535","title":"BRIEF-Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2512964535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512964535?lang=en_us&edition=fundamental","pubTime":"2025-02-17 09:38","pubTimestamp":1739756290,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical HoldFeb 17  - Neurizon Therapeutics Ltd NUZ.AX:GOT GUIDANCE FROM US FDA PLACING CO'S IND APPLICATION FOR NUZ-001 UNDER CLINICAL HOLDFurther company coverage: NUZ.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nFWN3OR2CY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2512506939","title":"Neurizon Therapeutics - Got Guidance From US FDA Placing Co's Ind Application for Nuz-001 Under Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2512506939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512506939?lang=en_us&edition=fundamental","pubTime":"2025-02-17 06:15","pubTimestamp":1739744139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250216:nFWN3OR2CY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2509658447","title":"Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509658447","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509658447?lang=en_us&edition=fundamental","pubTime":"2025-02-05 12:00","pubTimestamp":1738728037,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  received a US Patent for the use of its neurodegenerative diseases and cancer drug candidate NUZ-001, the company said in a Wednesday Australian bourse filing.The patent provides protection for NUZ-001 and related compounds used in treatments for mTOR pathway-related diseases in the US market until 2039, added the filing.Neurizon Therapeutics' shares were up 16% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2509250417","title":"BRIEF-Neurizon Therapeutics Says US Patent Granted For NUZ-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2509250417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509250417?lang=en_us&edition=fundamental","pubTime":"2025-02-05 09:19","pubTimestamp":1738718389,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Says US Patent Granted For NUZ-001Feb 5 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:US PATENT GRANTED FOR NUZ-001 FOR TREATMENT OF NEURODEGENERATIVE DISEASESFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OV12U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2509419922","title":"BUZZ-Australia's Neurizon Therapeutics rise on US patent approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2509419922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509419922?lang=en_us&edition=fundamental","pubTime":"2025-02-05 07:54","pubTimestamp":1738713280,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics rise on US patent approval** Shares of Neurizon Therapeutics NUZ.AX rise 12% to A$0.14* Stock hit highest level since Jan.20** Biotech firm receives U.S. patent for NUZ-001 for treatment of neurodegenerative diseases** Adds, patent grant follows FDA's Orphan Drug Designation for NUZ-001 in May 2024** Stock down 26.5% this year as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nL4N3OV2J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2509419358","title":"Neurizon snags US patent for NUZ-001 after winning FDA orphan status in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2509419358","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509419358?lang=en_us&edition=fundamental","pubTime":"2025-02-05 07:45","pubTimestamp":1738712700,"startTime":"0","endTime":"0","summary":"Neurizon  has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, designated orphan status by the FDA last year.The microcap stock jumped +12% to 14cps in early trades, per Cboe live pricing data.The State-side move ultimately firms up Neurizon’s Intellectual Property  portfolio and assists the company in commercialising NUZ-001 down the line should it continue to pass approval hurdles.To that end, also included in the patent are “structurally related compounds.”Licensing negotiations would also be emboldened by the presence of a patent, the company wrote on Wednesday.The patent is a ‘method of use’ patent; NUZ-001 is primarily targeting amyotrophic lateral sclerosis  and motor neurone disease  at this time.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any inves","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizon-snags-us-patent-for-nuz-001-after-winning-fda-orphan-status-in-2024-2025-02-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","BK4136","BK7055","IP","BK4585","MND.AU","BK4588","LU2463526074.USD","BK7096"],"gpt_icon":0},{"id":"2509149074","title":"Neurizon Therapeutics Ltd - US Patent Granted for Nuz-001 for Treatment of Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509149074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509149074?lang=en_us&edition=fundamental","pubTime":"2025-02-05 06:18","pubTimestamp":1738707538,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nFWN3OV12U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"gpt_icon":0},{"id":"2504970620","title":"ASX Market Update: Rio Tinto & Glencore in merger talks | January 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2504970620","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504970620?lang=en_us&edition=fundamental","pubTime":"2025-01-17 10:05","pubTimestamp":1737079500,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.21% at 8,345 points.The Discretionary sector has been the best performer, up 0.8%, followed closely by Utilities, up 0.75% and Industrials, up 0.7%.Rio Tinto Ltd has been down 0.6% as rumours of a merger with Glencore swirl. Talks are reported to be in the embryonic stages of development.Lynas Rare Earths has been down 3.7% after reporting a rise in sales revenues to $141.2 million and sales receipts to $145.9M during the second quarter of the 2025 fiscal year.Neurizon Therapeutics has been down 26.5% the US Food and Drug Administration has placed a clinical hold on its investigational new drug application for NUZ-001.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-rio-tinto-glencore-in-merger-talks-january-17-2025-2025-01-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NUZ.AU","RIO.AU","LYC.AU","BK7507","BK7511","BK7095","BK7096"],"gpt_icon":0},{"id":"2504197697","title":"BUZZ-Australia's Neurizon Therapeutics slides after FDA puts drug application on hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2504197697","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504197697?lang=en_us&edition=fundamental","pubTime":"2025-01-17 09:31","pubTimestamp":1737077511,"startTime":"0","endTime":"0","summary":"** Shares of Neurizon Therapeutics    fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024   ** Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020   ** Biotech firm receives notification from the U.S. FDA that its investigational new drug  application for NUZ-001 to treat amyotrophic lateral sclerosis , a neurodegenerative disease, has been put under clinical hold    ** IND application is a request for authorisation to administer experimental drugs to humans   ** Co says FDA has outlined certain concerns over sufficiency of information to assess application   ** More than 2.9 mln shares change hands, 7.1 times the 30-day avg   ** Neurizon down 26.5% YTD, including current session's moves ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096","BK4139","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[]}}